Vullo C M, Pesoa S A, Onetti C M, Riera C M
J Rheumatol. 1987 Apr;14(2):221-5.
HLA-DR antigens and cellular sensitivity to native bovine type I and type II collagen and proteoglycans were examined in patients with classic rheumatoid arthritis (RA) and normal individuals. Fifty eight percent of patients with RA (n = 88) and 28% of normals (n = 52) were DR4+ (pc less than 0.01). DR4 phenotype was significantly increased in patients with severe disease stages (III-IV), as defined by the ARA criteria, in contrast to those showing mild disease stages (I-II) (p less than 0.05). Furthermore, peripheral blood mononuclear cells from 55 patients and 30 controls were evaluated for the in vitro production of leukocyte inhibitory factor in response to native type I and type II collagen and proteoglycans. By using this assay, cells from the arthritic group exhibited a statistically significant response when stimulated with native type I collagen and proteoglycans. The cellular immune response was not associated with any particular HLA-DR antigens, or to the disease stage or severity.
在经典类风湿性关节炎（RA）患者和正常个体中检测了HLA - DR抗原以及细胞对天然牛I型和II型胶原蛋白和蛋白聚糖的敏感性。88例RA患者中有58%以及52例正常个体中有28%为DR4 +（p小于0.01）。根据美国风湿病学会（ARA）标准定义，与疾病轻度阶段（I - II）的患者相比，疾病严重阶段（III - IV）的患者中DR4表型显著增加（p小于0.05）。此外，对55例患者和30例对照的外周血单个核细胞进行了评估，以检测其对天然I型和II型胶原蛋白以及蛋白聚糖的体外白细胞抑制因子产生情况。通过该检测方法，关节炎组的细胞在用天然I型胶原蛋白和蛋白聚糖刺激时表现出统计学上的显著反应。细胞免疫反应与任何特定的HLA - DR抗原、疾病阶段或严重程度均无关。
